Clinical Trial Update: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous versus intravenous nivolumab in previously treated advanced or metastatic clear cell renal cell carcinoma; status is active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Clear Cell Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING